La rapamicina prolonga la esperanza de vida en ratones de laboratorio de forma más fiable que cualquier otro fármaco conocido, incluso cuando el tratamiento empieza en la vejez. Ese único resultado en animales es la razón por la que ocupa el centro de la conversación sobre longevidad. También es un medicamento con receta establecido, usado para prevenir el rechazo del trasplante de órganos y para tratar algunas enfermedades específicas. Nunca se ha demostrado que prolongue la esperanza de vida ni la vida saludable en humanos.
Los ensayos en humanos realizados hasta ahora miden la respuesta inmunitaria y la viabilidad. Un gran ensayo de fase 3 no alcanzó su objetivo principal. El fármaco conlleva inmunosupresión, riesgo de infección, úlceras bucales y efectos sobre el azúcar en sangre y los lípidos. No se ha establecido una dosis segura para el envejecimiento.
Findings & Outcomes
What It Is
Rapamycin is a compound first isolated in the twentieth century from a soil bacterium found on Easter Island. Its name comes from the island's local name, Rapa Nui. As the drug sirolimus, it has been used in medicine for decades. Its main job there is to suppress the immune system after an organ transplant, so the body does not reject the new organ. It also coats the stents that hold coronary arteries open. Two close relatives, everolimus and temsirolimus, treat certain cancers and the rare disease tuberous sclerosis.
Rapamycin became the most discussed molecule in aging research for a reason separate from all of that. It acts on a growth-control pathway called mTOR, and dialing that pathway down is the intervention the whole longevity case rests on. That has produced a large and growing off-label use: people take rapamycin hoping to slow their own aging, well ahead of any human trial.
Anatomy
1The mTOR pathway
mTOR, the mechanistic target of rapamycin, is a master growth switch inside every cell. It senses nutrients and growth signals and, when they are plentiful, drives the cell to build proteins and grow while holding back cellular recycling. Turning mTOR down slows growth and steps up autophagy, the process that clears out worn-out cellular parts. This is the pathway the whole longevity case runs through.
2Sirolimus, the original drug
Sirolimus is rapamycin as a licensed medicine. It is given orally to prevent kidney transplant rejection and to treat the rare lung disease lymphangioleiomyomatosis, and it coats drug-eluting cardiac stents. It is the form with the longest human safety record, gathered mostly in transplant patients taking it continuously at doses set to suppress the immune system.
3Everolimus and the analogues
Everolimus and temsirolimus are chemical relatives of rapamycin, the class often called rapalogs. Everolimus is approved for several cancers, for tuberous sclerosis, and in transplant medicine. In aging research the low-dose, short-course use of everolimus is what produced the human immune findings, at doses well below those used to prevent transplant rejection.
How It Works
Rapamycin inhibits mTOR complex 1, the branch of the mTOR pathway that governs cell growth. It acts indirectly. The drug first binds a small intracellular protein called FKBP12. That pair then latches onto mTOR complex 1 and shuts much of its activity down.
When mTOR complex 1 is active, the cell responds as if nutrients are abundant: it builds proteins, grows, and slows recycling. Inhibiting the complex reverses that: the cell lowers its building and switches on autophagy, the housekeeping process that breaks down and recycles damaged parts. The result reproduces much of the cellular state that fasting produces.
That link is why aging biology keeps returning to the drug. Nutrient sensing is one of the recognized hallmarks of aging, and mTOR is its central node. A drug that turns the node down is a direct test of the idea that dialing back growth signaling slows aging. For where mTOR fits among the other drivers, see the biology of aging.
Prolonged or higher-dose rapamycin also disturbs a second complex, mTOR complex 2. That second effect is tied to the drug's influence on blood sugar and insulin. It is the mechanism behind the metabolic risks listed later.
What It Does
The animal record is the strongest in longevity research. In the National Institute on Aging Interventions Testing Program, rapamycin extended the lifespan of genetically diverse mice. The program runs each compound at three separate laboratories to screen out fluke results, and the rapamycin result held up to replication. It worked even when treatment began at roughly the human equivalent of age 60. No other longevity molecule has an animal record this consistent, which is why the mouse findings sit at the top of the ladder below. Still, a lifespan gain in mice is a reason to study the drug in people. It is not yet proof of anything in humans.
The human evidence sits lower. It measures immunity and feasibility, and it has not measured lifespan at all. No completed trial has tested whether rapamycin extends human life or healthspan. The signals that exist are narrow immune findings in adults over 65, measured over weeks to a year. One large phase-3 trial of the mTOR inhibitor RTB101, given on its own, missed its main infection endpoint. So the human evidence is still preliminary. Trials of physical function in healthy people are small and early.
Most of what is known about rapamycin's side effects comes from the approved uses. There, sirolimus, everolimus, and temsirolimus are dosed continuously, at levels set to suppress the immune system or hold back a tumor. None of those licensed indications is aging.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
How it works
La rapamicina inhibe mTORC1, imitando un ayuno leve y activando la autofagia
La rapamicina reduce la actividad de mTOR, el interruptor maestro que una célula usa para detectar nutrientes y equilibrar el crecimiento frente al reciclaje. Reducirla imita un ayuno leve y activa la autofagia, el reciclaje de piezas desgastadas.
La rapamicina (sirolimus) forma un complejo con la proteína de unión a FK506 de 12 kDa (FKBP12), que se une al complejo mTOR 1 y lo inhibe. El mTORC1 integra señales de aminoácidos, factores de crecimiento y el estado energético para impulsar la biogénesis de ribosomas, la síntesis de proteínas y lípidos, y el crecimiento celular, y suprime la macroautofagia. Inhibir mTORC1 reduce por tanto la actividad anabólica y libera la represión de la autofagia, reproduciendo gran parte del estado celular que produce la escasez de nutrientes y la restricción calórica. La exposición prolongada o a dosis más altas también afecta al segundo complejo, mTORC2, que es relevante para los efectos metabólicos observados con el fármaco.
The study · 1
Saxton and Sabatini, mTOR Signaling in Growth, Metabolism, and Disease · Cell 2017;169(2):361-371
Respiratory Infection
Un inhibidor de mTOR en dosis bajas redujo las infecciones respiratorias en adultos mayores durante el año siguiente
En un ensayo de seguimiento más amplio, un inhibidor de mTOR en dosis bajas redujo el número de infecciones respiratorias en adultos mayores a lo largo de un año. Es la señal humana más sólida de que reducir la actividad de mTOR puede respaldar la función inmunitaria con la edad.
Mannick y colegas (2018) asignaron aleatoriamente a 264 adultos mayores a combinaciones del inhibidor de mTOR RTB101 y everolimus o a placebo, y hicieron seguimiento de las infecciones de las vías respiratorias durante un año. El régimen que combinaba dosis bajas de ambos fármacos redujo la tasa de infecciones respiratorias confirmadas por laboratorio y se asoció con una firma génica antiviral regulada al alza, lo que amplía el hallazgo anterior sobre la vacuna a un criterio de valoración clínico de infección.
The study · 1
Mannick et al., TORC1 inhibition enhances immune function and reduces infections in the elderly · Sci Transl Med 2018;10(449):eaaq1564
Blood Sugar
La rapamicina crónica causó resistencia a la insulina en ratones al alterar mTORC2
La rapamicina a largo plazo puede causar resistencia a la insulina, y en ratones esto procede de afectar a un segundo complejo mTOR. Esto sugiere que la desventaja metabólica y el beneficio de longevidad podrían discurrir por ramas distintas de la vía.
Lamming y colegas (2012) demostraron que la rapamicina crónica en ratones altera el complejo mTOR 2 (mTORC2) además del mTORC1, y que la pérdida de la señalización de mTORC2 en el hígado impulsa la intolerancia a la glucosa y la resistencia a la insulina observadas con el fármaco. Dado que la prolongación de la esperanza de vida se atribuye principalmente a la inhibición de mTORC1, el trabajo planteó la posibilidad de que el coste metabólico y el beneficio de longevidad sean, al menos en principio, separables.
The study · 1
Lamming et al., Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity · Science 2012;335(6076):1638-1643
La rapamicina dejó a los ratones intolerantes a la glucosa pero todavía sensibles a la insulina
El efecto de la rapamicina sobre el azúcar en sangre en ratones es mixto: empeora el manejo de la glucosa en una prueba mientras preserva la sensibilidad a la insulina en otra. El panorama metabólico es más complicado que una sola etiqueta.
Lamming y colegas (2013) encontraron que ratones jóvenes y viejos genéticamente heterogéneos alimentados con rapamicina fueron intolerantes a la glucosa en una prueba de sobrecarga de glucosa pero se mantuvieron sensibles a la insulina, un desacoplamiento que no coincide con el patrón habitual de la diabetes tipo 2. El hallazgo agudiza la cuestión metabólica en lugar de descartarla, porque la intolerancia a la glucosa y los triglicéridos y el colesterol elevados también están documentados en personas que toman el fármaco por trasplante de órganos.
The study · 1
Lamming et al., Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive · Aging Cell 2013;12(4):712-718
Immune Function
Seis semanas de un inhibidor de mTOR elevaron la respuesta de anticuerpos a la vacuna de la gripe en adultos mayores en aproximadamente un 20 %
Un ciclo corto de un inhibidor de mTOR mejoró la respuesta de los adultos mayores a la vacuna de la gripe. Se trata de un hallazgo inmunitario humano puntual, no de evidencia sobre la esperanza de vida.
Mannick y colegas (2014) asignaron aleatoriamente a 218 adultos de 65 años o más a dosis bajas del análogo de rapamicina everolimus o a placebo durante seis semanas antes de la vacunación estacional contra la gripe. El everolimus en dosis bajas mejoró la respuesta de anticuerpos a la vacuna en aproximadamente un 20 % y redujo la proporción de subconjuntos de células inmunitarias agotadas y senescentes, lo que sugiere que la inhibición de mTOR puede revertir parcialmente aspectos del envejecimiento inmunitario. Las dosis fueron más bajas y se administraron durante un periodo más corto que las utilizadas para prevenir el rechazo de trasplantes.
The study · 1
Mannick et al., mTOR inhibition improves immune function in the elderly · Sci Transl Med 2014;6(268):268ra179
Longevity And Mortality
La rapamicina iniciada tarde elevó la esperanza de vida de los ratones aproximadamente un 9 % en machos y un 14 % en hembras
La rapamicina es el fármaco más fiable conocido para alargar la esperanza de vida en ratones, y funciona incluso cuando se empieza en la vejez. El hallazgo se ha repetido en un riguroso programa multicéntrico, razón por la cual es el resultado animal insignia.
Harrison y colegas (2009) informaron de que la rapamicina administrada a ratones genéticamente heterogéneos a partir de los 600 días de edad prolongó la esperanza de vida media y máxima en ambos sexos, un resultado llamativo porque el tratamiento comenzó tarde en la vida. Miller y colegas (2011) confirmaron la prolongación de la esperanza de vida con rapamicina en el mismo Interventions Testing Program multicéntrico, mientras que el resveratrol y la simvastatina no la prolongaron, lo que refuerza el hallazgo mediante replicación independiente. El Interventions Testing Program prueba compuestos en tres centros en una población de ratones genéticamente diversa precisamente para reducir los falsos positivos.
The studies · 2
Harrison et al., Rapamycin fed late in life extends lifespan in genetically heterogeneous mice · Nature 2009;460(7253):392-395
Miller et al., Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice · J Gerontol A Biol Sci Med Sci 2011;66(2):191-201
Una dosis tres veces mayor prolongó la esperanza de vida de los ratones aproximadamente un 23 % en machos y un 26 % en hembras
El efecto sobre la esperanza de vida en ratones crece con dosis más altas y difiere entre machos y hembras, lo que muestra que el beneficio está relacionado con la dosis y no es simplemente lo mismo que comer menos.
Miller y colegas (2014) probaron dosis más altas de rapamicina en ratones genéticamente heterogéneos y encontraron mayores ganancias en la esperanza de vida que con la dosis original, con una clara relación dosis-respuesta y diferencias por sexo constantes en la magnitud del efecto. Los autores también informaron de que los cambios metabólicos que acompañaban a la rapamicina diferían de los producidos por la restricción dietética, lo que indica que ambas intervenciones prolongan la vida por vías al menos parcialmente distintas.
The study · 1
Miller et al., Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction · Aging Cell 2014;13(3):468-477
Cognition
La rapamicina crónica mejoró el aprendizaje y redujo la conducta similar a la ansiedad en ratones
En ratones, la rapamicina a largo plazo mejoró el aprendizaje y redujo la conducta similar a la ansiedad. Es una señal animal temprana para el cerebro, no un efecto demostrado en personas.
Halloran y colegas (2012) administraron a ratones rapamicina crónica a lo largo de toda la vida y encontraron mejoras en pruebas de aprendizaje y memoria junto con una reducción de las conductas de tipo ansioso y depresivo, acompañadas de niveles cerebrales más altos de varios neurotransmisores. El trabajo es una pista mecanicista temprana sobre los efectos de la inhibición de mTOR en el cerebro que envejece, y no evidencia de un beneficio cognitivo en humanos.
The study · 1
Halloran et al., Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice · Neuroscience 2012;223:102-113
Muscle And Strength
Ocho semanas de rapamicina no mostraron una ganancia clara de rendimiento físico en adultos mayores sanos
Un ensayo humano pequeño y de corta duración encontró que la rapamicina era tolerable en adultos mayores sanos, pero no mostró una mejora clara en la función física. Los ensayos humanos de longevidad con criterios de valoración de función física apenas están surgiendo ahora.
Kraig y sus colegas (2018) asignaron aleatoriamente a 25 adultos mayores sanos a ocho semanas de rapamicina o placebo para probar la viabilidad y la seguridad, siguiendo medidas inmunitarias, de rendimiento físico y cognitivas. El fármaco se toleró sin efectos adversos graves, y no se observó un cambio claro en el rendimiento físico, la cognición ni la mayoría de las medidas inmunitarias en este estudio pequeño y breve, diseñado para establecer la viabilidad y no para detectar un efecto. La única señal de laboratorio constante fueron descensos estadísticamente significativos en varias medidas de la serie roja, incluidos hemoglobina, hematocrito y recuento de glóbulos rojos, que los autores consideraron sin relevancia clínica en un estudio tan breve. Esfuerzos mayores fuera de indicación, como el ensayo PEARL, que usa criterios de función física, siguen siendo preliminares.
The study · 1
Kraig et al., A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort · Exp Gerontol 2018;105:53-69
The Off-Label Gap
Between the strong animal data and the thin human data sits a large off-label experiment. Most users take rapamycin on an intermittent schedule. Transplant medicine, by contrast, uses continuous dosing. The off-label idea is that spaced doses might keep the growth-slowing effect while easing the load on the immune system. That reasoning is a hypothesis drawn from animal work and pharmacology. No completed human longevity trial has confirmed it.
The human function data is small and short. A feasibility trial gave healthy older adults an eight-week course and found it tolerable. Over that span it produced no clear change in physical performance, cognition, or most immune measures. Its one consistent laboratory signal was a statistically significant drop in several red-cell measures, including hemoglobin, hematocrit, and red blood cell count. The investigators judged that drop not clinically significant over the short trial. Larger efforts such as the PEARL trial, which uses physical-function endpoints, are still preliminary.
Rapamycin is a prescription immunosuppressant, not a supplement, and no completed human trial establishes a safe or effective dose for slowing aging in a healthy person.
The animal case is strong, the human aging case is early, and the best schedule for a healthy person is unknown. The risks are documented in the Cautions below.
Go Deeper
- The biology of aging: where rapamycin and mTOR sit among the hallmarks of aging, and how to read an animal drug result against the human evidence.
- Autophagy: the cellular recycling process rapamycin switches on by inhibiting mTOR, and the mechanism much of the longevity case runs through.
- Peptides: another category where a few approved drugs sit alongside a large off-label market, and how to keep the two apart.
- IV therapy and NAD: a neighboring anti-aging pitch, and the same distinction between moving a marker and changing an outcome.
The Chinese Medicine View
Rapamycin is a modern isolate, so no classical Chinese entry exists for it. No historical text assigns it a channel, a temperature, or a flavor, and no traditional formula contains it. Nothing suggests any herb or formula reproduces what rapamycin does.
The tradition does reason about the territory the drug acts on. In cellular terms, rapamycin mimics a fasting signal: it lowers building in a well-fed cell and clears out what is worn. That sits close to a deep theme in Chinese medicine, the idea in Yang Sheng, the cultivation of life, that moderation and restraint conserve the body's reserves. Classical counsel to stop eating before fullness, and the long practice of periodic simplicity in eating, reach the same place by observation. Nutrient-sensing biology points the same way: constant abundance and constant growth signaling appear to accelerate aging.
The tradition also holds a caution that fits here. Tonifying, or building the body up, is appropriate only when there is a true deficiency and the person can assimilate what is given. Push past that, and the same effort depletes the body instead of restoring it. A drug that suppresses the immune system and disturbs the transformation of nourishment is, in that framing, a powerful intervention with a cost.
The drug stands or falls on the trials. The animal trials are numerous; trials in healthy humans are almost none.
Cautions
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
A dosis de tratamiento, el sirolimus causó habitualmente úlceras bucales, colesterol elevado y diarrea
McCormack y colegas (2011) asignaron aleatoriamente a 89 mujeres con linfangioleiomiomatosis a sirolimus o placebo durante un año. El sirolimus estabilizó la función pulmonar durante el tratamiento, y el ensayo documentó su perfil de efectos adversos: mucositis (úlceras bucales), efectos gastrointestinales como diarrea y náuseas, erupción acneiforme, hipercolesterolemia y edema periférico se presentaron con más frecuencia que con placebo. El beneficio en la función pulmonar se perdió tras suspender el fármaco, lo que subraya que estos efectos acompañan a la dosificación terapéutica continua.McCormack et al., Efficacy and safety of sirolimus in lymphangioleiomyomatosis
Prescription drug, immune-suppressing
Rapamycin is a prescription drug whose primary action is to suppress the immune system. At the doses used in transplant medicine it lowers immune defenses enough to raise the risk of infections, including serious ones, and it requires blood-level monitoring and medical oversight. Whatever the longevity hopes attached to it, it belongs in the hands of a clinician who can weigh that risk for a given person.
Infection risk
Because it dampens immune function, rapamycin can make infections more likely and harder to clear. This is the central trade-off of the drug and the reason the aging research uses lower, spaced doses in the hope of reducing it. Whether intermittent dosing avoids meaningful immunosuppression in a healthy person is not established.
Mouth ulcers and impaired wound healing
Mouth ulcers, or mucositis, are among the most common side effects. Rapamycin also slows wound healing, so surgeons often pause it around operations. Anyone facing surgery or dealing with a wound needs a clinician to manage the drug, not a schedule found online.
Effects on blood sugar and lipids
Rapamycin can raise cholesterol and triglycerides and can worsen glucose handling. In animals the metabolic picture is mixed, and in transplant patients these changes are well documented. They are part of the risk that any longevity use has to account for.
Drug interactions
Rapamycin is processed by liver enzymes that many other drugs and even grapefruit affect, so its blood levels can swing up or down when combined with common medications. This is one more reason its use requires a prescriber who knows the full medication list, not self-management.
Not a do-it-yourself longevity drug
If rapamycin interests you, the responsible step is a clinician who can order blood-level monitoring and weigh the risks for you. No home protocol substitutes for that oversight while the aging trials are unfinished.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
Does rapamycin actually extend lifespan?
Living longer and staying healthy longer are different questions, and rapamycin's mouse data speaks mainly to the first. No human study has followed people long enough to measure either one directly. That is why aging research leans on shorter-term markers instead of years of life, and why a confident human lifespan claim is not yet possible.
Is rapamycin approved for anything?
Yes, for several specific diseases, all covered above. What matters for aging is what is missing from that list: no regulator has approved rapamycin, or any drug, for aging itself. Every longevity use therefore falls outside the label. That gap is the whole reason the practice is called off-label.
Why do some people take rapamycin off-label for aging?
The reasoning is covered above. Off-label has a specific legal meaning: a clinician may legally prescribe an approved drug for a purpose it was never approved for, at their own discretion. That is how rapamycin reaches healthy people while the aging trials are still unfinished. It also means the prescriber and the patient, not a regulator, carry the evidence burden.
What are the main risks of rapamycin?
The specific risks are listed in the Cautions above. The deciding factor is supervision. In its approved uses rapamycin comes with blood-level testing and a clinician watching for infection; someone self-sourcing it for aging has neither. The same molecule therefore carries a different real-world risk depending on whether anyone is monitoring it.
Can a Chinese herb or formula do what rapamycin does?
No. No herb or formula has been shown to inhibit mTOR the way rapamycin does. TheOverlap is a shared idea about restraint, not a shared mechanism. Fasting and dietary restraint engage the same mTOR pathway at no cost, and both are open to anyone.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 11 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.